h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
inc
first
case
report
decemb
infect
sever
acut
respiratori
coronaviru
becom
worldwid
pandem
ill
caus
overwhelm
health
care
system
global
symptom
infect
vari
wide
asymptomat
diseas
pneumonia
lifethreaten
complic
includ
acut
respiratori
distress
syndrom
multisystem
organ
failur
ultim
death
older
patient
preexist
respiratori
cardiovascular
condit
appear
greatest
risk
sever
complic
absenc
proven
effect
therapi
current
manag
consist
support
care
includ
invas
noninvas
oxygen
support
treatment
antibiot
addit
mani
patient
receiv
offlabel
compassionateus
therapi
includ
antiretrovir
antiparasit
agent
antiinflammatori
compound
convalesc
plasma
remdesivir
prodrug
nucleotid
analogu
intracellularli
metabol
analogu
adenosin
triphosph
inhibit
viral
rna
polymeras
remdesivir
broadspectrum
activ
member
sever
viru
famili
includ
filovirus
eg
ebola
coronavirus
eg
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
shown
prophylact
therapeut
efficaci
nonclin
model
coronavirus
vitro
test
also
shown
remdesivir
activ
remdesivir
appear
favor
clinic
safeti
profil
report
basi
experi
approxim
person
includ
healthi
volunt
patient
treat
acut
ebola
viru
infect
support
data
file
share
world
health
organ
report
describ
outcom
cohort
patient
hospit
sever
treat
remdesivir
compassionateus
basi
gilead
scienc
began
accept
request
clinician
compassion
use
remdesivir
januari
submit
request
clinician
complet
assess
form
demograph
diseasestatu
inform
patient
see
supplementari
appendix
avail
full
text
articl
nejmorg
approv
request
reserv
hospit
patient
infect
confirm
reversetranscriptasepolymerasechainreact
assay
either
oxygen
satur
less
patient
breath
ambient
air
need
oxygen
support
addit
patient
requir
creatinin
clearanc
ml
per
minut
serum
level
alanin
aminotransferas
alt
aspart
aminotransferas
ast
less
five
time
upper
limit
normal
rang
agre
use
investig
agent
approv
case
plan
treatment
cours
remdesivir
consist
load
dose
mg
intraven
day
plu
mg
daili
follow
day
support
therapi
provid
discret
clinician
followup
continu
least
day
begin
treatment
remdesivir
discharg
death
data
collect
march
report
openlabel
program
predetermin
number
patient
number
site
durat
data
patient
includ
analysi
report
previous
detail
studi
design
conduct
seen
protocol
avail
nejmorg
data
patient
oxygensupport
requir
advers
event
laboratori
valu
includ
serum
creatinin
alt
ast
report
daili
day
day
addit
followup
inform
solicit
day
although
prespecifi
end
point
program
quantifi
incid
key
clinic
event
includ
chang
oxygensupport
requir
ambient
air
lowflow
oxygen
nasal
highflow
oxygen
noninvas
posit
pressur
ventil
nippv
invas
mechan
ventil
extracorpor
membran
oxygen
ecmo
hospit
discharg
report
advers
event
includ
lead
discontinu
treatment
seriou
advers
event
death
addit
evalu
proport
patient
clinic
improv
defin
live
discharg
hospit
decreas
least
point
baselin
modifi
ordin
scale
recommend
r
blueprint
group
sixpoint
scale
consist
follow
categori
hospit
hospit
requir
supplement
oxygen
hospit
requir
supplement
oxygen
hospit
requir
nasal
highflow
oxygen
therapi
noninvas
mechan
ventil
hospit
requir
invas
mechan
ventil
ecmo
death
regulatori
institut
review
board
independ
ethic
committe
approv
obtain
patient
treat
remdesivir
consent
obtain
patient
accord
local
regul
program
design
conduct
sponsor
gilead
scienc
accord
protocol
sponsor
collect
data
monitor
conduct
program
perform
statist
analys
author
access
data
assum
respons
integr
complet
report
data
initi
draft
manuscript
prepar
writer
employ
gilead
scienc
along
one
author
input
author
samples
calcul
perform
analysi
popul
includ
patient
receiv
first
dose
remdesivir
march
clinic
data
least
subsequ
day
avail
clinic
improv
mortal
remdesivir
compassionateus
cohort
describ
use
kaplanmei
analysi
associ
pretreat
characterist
outcom
evalu
cox
proport
hazard
regress
analysi
includ
provis
correct
multipl
comparison
test
associ
baselin
variabl
outcom
result
report
point
estim
confid
interv
width
confid
interv
adjust
multipl
comparison
interv
use
infer
definit
associ
outcom
analys
conduct
sa
softwar
version
sa
institut
total
patient
receiv
least
one
dose
remdesivir
march
patient
exclud
miss
postbaselin
inform
patient
erron
remdesivir
start
date
patient
fig
supplementari
appendix
remain
patient
includ
analysi
receiv
full
cours
remdesivir
receiv
day
treatment
fewer
day
treatment
tabl
show
baselin
demograph
clinic
characterist
patient
compassionateus
cohort
patient
enrol
unit
state
patient
japan
itali
austria
franc
germani
netherland
spain
canada
total
patient
men
age
rang
year
median
age
year
interquartil
rang
baselin
major
patient
receiv
invas
ventil
includ
receiv
mechan
ventil
receiv
ecmo
median
durat
invas
mechan
ventil
initi
remdesivir
treatment
day
interquartil
rang
compar
patient
receiv
noninvas
oxygen
support
baselin
receiv
invas
ventil
tend
older
median
age
year
vs
year
like
male
vs
higher
median
serum
alt
u
per
liter
vs
creatinin
mg
per
decilit
vs
per
liter
vs
higher
preval
coexist
condit
includ
hypertens
vs
diabet
vs
hyperlipidemia
vs
asthma
vs
median
durat
symptom
initi
remdesivir
treatment
day
interquartil
rang
differ
substanti
patient
receiv
invas
ventil
receiv
noninvas
ventil
tabl
median
followup
day
interquartil
rang
receiv
first
dose
h
e
ne
w
e
ngl
nd
jou
r
na
l
f
e
dicin
remdesivir
patient
show
improv
categori
oxygen
support
wherea
patient
show
worsen
fig
improv
observ
patient
breath
ambient
air
receiv
lowflow
supplement
oxygen
patient
receiv
noninvas
oxygen
support
nippv
highflow
supplement
oxygen
notabl
patient
receiv
invas
mechan
ventil
extub
patient
receiv
ecmo
stop
receiv
aliv
last
followup
individu
patient
chang
categori
oxygen
support
shown
figur
date
recent
followup
patient
fig
clinic
improv
less
frequent
among
patient
receiv
invas
ventil
among
receiv
noninvas
ventil
hazard
ratio
improv
ci
fig
among
patient
year
age
older
hazard
ratio
compar
patient
younger
year
ci
fig
sex
region
enrol
coexist
condit
durat
symptom
remdesivir
treatment
initi
significantli
associ
clinic
improv
tabl
seven
patient
die
complet
remdesivir
treatment
includ
patient
receiv
invas
ventil
receiv
noninvas
oxygen
support
see
supplementari
appendix
case
narr
median
interv
remdesivir
initi
death
day
interquartil
rang
overal
mortal
date
admiss
per
hospit
day
ci
differ
substanti
among
patient
receiv
invas
ventil
per
hospit
day
ci
compar
receiv
noninvas
ventil
per
hospit
day
ci
risk
death
greater
among
patient
year
age
older
hazard
ratio
compar
patient
younger
year
ci
among
higher
serum
creatinin
baselin
hazard
ratio
per
milligram
per
decilit
ci
hazard
ratio
patient
receiv
invas
ventil
compar
receiv
noninvas
oxygen
support
ci
tabl
total
patient
report
advers
event
followup
tabl
common
advers
event
increas
hepat
enzym
diarrhea
rash
renal
impair
hypotens
gener
advers
event
common
patient
receiv
invas
ventil
total
patient
seriou
advers
event
group
treatment
common
seriou
advers
event
multipleorgandysfunct
syndrom
septic
shock
acut
kidney
injuri
hypotens
report
patient
receiv
invas
ventil
baselin
four
patient
discontinu
remdesivir
treatment
prematur
one
worsen
preexist
renal
failur
one
multipl
organ
failur
two
elev
aminotransferas
includ
one
patient
maculopapular
rash
given
natur
compassionateus
program
data
limit
number
laboratori
measur
collect
median
serum
alt
ast
creatinin
fluctuat
followup
fig
date
therapi
demonstr
efficaci
patient
preliminari
report
describ
clinic
outcom
small
cohort
patient
sever
ill
treat
remdesivir
although
data
sever
ongo
random
control
trial
soon
provid
inform
evid
baselin
day
day
treatment
remdesivir
rdv
initi
final
oxygen
support
status
shown
base
recent
report
data
patient
color
line
repres
oxygensupport
statu
patient
time
color
circl
left
line
indic
patient
overal
chang
statu
baselin
patient
statu
improv
oxygensupport
statu
improv
last
followup
patient
discharg
vertic
black
mark
show
last
day
treatment
rdv
gray
dash
line
repres
miss
data
patient
recent
report
oxygen
statu
event
death
discharg
last
dose
rdv
solid
squar
end
line
indic
patient
die
open
diamond
indic
patient
discharg
hospit
neither
squar
diamond
end
line
neither
death
discharg
occur
patient
breath
ambient
air
day
patient
discharg
day
clinic
improv
shown
full
cohort
cohort
stratifi
accord
ventil
statu
baselin
cohort
stratifi
age
regard
safeti
efficaci
remdesivir
outcom
observ
compassionateus
program
best
current
avail
data
specif
improv
oxygensupport
statu
observ
patient
overal
mortal
median
followup
day
recent
random
control
trial
lopinavirritonavir
patient
hospit
mortal
import
note
patient
trial
receiv
invas
ventil
baselin
case
seri
cohort
studi
larg
china
mortal
rate
report
sever
case
defin
need
admiss
intens
care
unit
invas
ventil
exampl
among
patient
hospit
wuhan
china
mortal
overal
among
patient
receiv
invas
mechan
ventil
way
comparison
mortal
observ
remdesivir
compassionateus
cohort
noteworthi
consid
sever
diseas
patient
popul
howev
patient
enrol
compassionatetreat
program
directli
compar
studi
port
exampl
remdesivirtr
patient
receiv
invas
ventil
baselin
includ
receiv
ecmo
mortal
subgroup
compar
patient
receiv
noninvas
oxygen
support
major
patient
male
year
age
coexist
condit
unfortun
compassionateus
program
collect
viral
load
data
confirm
antivir
effect
remdesivir
associ
baselin
viral
load
viral
suppress
clinic
respons
moreov
durat
remdesivir
therapi
entir
uniform
studi
larg
clinic
improv
enabl
discharg
hospit
effect
shorter
durat
therapi
eg
day
compar
day
would
allow
treatment
patient
pandem
assess
ongo
random
trial
therapi
new
safeti
signal
detect
shortterm
remdesivir
therapi
compassionateus
cohort
nonclin
toxicolog
studi
shown
renal
abnorm
clear
evid
nephrotox
due
remdesivir
therapi
observ
report
studi
healthi
volunt
patient
infect
ebola
viru
mildtomoder
elev
alt
ast
observ
cohort
patient
sever
howev
consid
frequenc
liver
dysfunct
patient
attribut
hepatotox
either
remdesivir
underli
diseas
challeng
nevertheless
safeti
sideeffect
profil
remdesivir
patient
requir
proper
assess
placebocontrol
trial
interpret
result
studi
limit
small
size
cohort
rel
short
durat
followup
potenti
miss
data
owe
natur
program
lack
inform
patient
initi
treat
lack
random
control
group
although
latter
preclud
definit
conclus
comparison
contemporan
cohort
literatur
gener
care
expect
consist
cohort
suggest
remdesivir
may
clinic
benefit
patient
sever
nevertheless
factor
may
contribut
differ
outcom
includ
type
support
care
eg
concomit
medic
variat
ventilatori
practic
differ
institut
treatment
protocol
threshold
hospit
moreov
use
invas
ventil
proxi
diseas
sever
may
influenc
avail
ventil
given
locat
find
uncontrol
data
inform
ongo
random
placebocontrol
trial
remdesivir
therapi
